Pediatric gliomas often harbor BRAF fusions (e.g., KIAA1549-BRAF) that also respond to dabrafenib, though the drug’s efficacy may vary depending on the specific mutation type and tumor microenvironment. The gene discussed is BRAF; the disease is neoplasm.